Specifically, peroxisome proliferator-activated receptor δ (PPARD) and peroxisome proliferator-activated receptor α (PPARA) have been suggested as therapeutic targets to alleviate NAFLD [5, 7]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.